Pharmafile Logo

Speak First

Speak First is all about three things – confidence, impact and clarity. Our communication skills training and coaching is guaranteed to enhance business relationships. With over 20 years’ experience, we are global specialists in soft skills training essential for business success. Our expertise include: presentation skills, personal impact, media training, selling and negotiation skills, business writing, NLP for Business and other interpersonal and communication skills training to improve workplace effectiveness and career success.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Amiculum

AMICULUM works with the global healthcare industry to bring science to life across the product lifecycle from early opportunity assessment through to launch and beyond. By listening to the changing…

View Profile

Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop great pharmaceutical brands. We do this by creating Pharmacohesion™.

View Profile

Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education to life science companies from around the globe since 2008.

View Profile

M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors with over 6 million members across M3-owned networks and an…

View Profile

OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health outcomes and patient wellbeing.

View Profile

Company Details

1st Floor, 20 Old Street, London, EC1V 9AB, United Kingdom
+44 (0)20 7253 2117

 Latest Content from PMHub 

Research Partnership and Janssen are 2017-18 BOBI Awards finalists

We are delighted to announce that an entry submitted by Research Partnership with Janssen has been selected as a finalist in the Best Business Impact category at this year’s BOBI...

Portfolio analysis: Making Go/No-Go decisions to optimise the portfolio

Tuesday 20th March 2018 11:00 EST / 16:00 GMT / 17:00 CEST

PMRC New Jersey round up 2018

Earlier this month, Directors Tom Nolte and Melinda Shorr attended the Pharmaceutical Market Research Conference in Newark, New Jersey

Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis

You can probably remember at least one of your friends in school who was always scratching and suffered from red, scaly skin rashes, perhaps on their elbows or backs of...

Good intentions, bad habits: Reforming mental healthcare in Latin America and the Caribbean

In the second of a series of articles exploring mental health in emerging markets we take an in-depth look at the situation in Latin America and the Caribbean

How we applied user-led design thinking in the ER setting to improve patient care

The challengeOur client needed to identify the key delivery-device attributes for an antibiotic topical treatment used to combat a group of infections typically affecting young children. Current treatment is a...

Research conducted by Research Partnership published in leading medical journal

Findings from a study conducted by Research Partnership have recently been published in the ‘Supportive Care in Cancer’ journal

The Lucid Festival of Magic

Lucid Group threw a spellbinding event to celebrate eleven years of transforming lives with their standout new branding taking centre stage.

The Periodic Table of Healthcare Communications 2018

The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing.

Managing local population needs is key for the NHS

Steve How, Paul Midgley and Sue Thomas, of Wilmington Healthcare, explore population-based planning in the NHS and what this means for pharma